Opko Health reports Q4 EPS 1c, consensus (10c)

Reports Q4 revenue $183.6M, consensus $155.42M. The company said, “Dosing of patients has commenced for the Phase I study (NCT06655324) of an EBV vaccine candidate being developed in collaboration with Merck. The investigational vaccine, based on ModeX’s ferritin nanoparticle vaccine platform, is being evaluated for safety and tolerability in up to 200 healthy adults. Commencement of this study triggered a milestone payment to ModeX…Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers.”